Opioid system in L-DOPA-induced dyskinesia

Jing Pan, Huaibin Cai

    Research output: Contribution to journalReview articlepeer-review

    Abstract

    L-3, 4-Dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) is a major clinical complication in the treatment of Parkinson's disease (PD). This debilitating side effect likely reflects aberrant compensatory responses for a combination of dopaminergic neuron denervation and repeated L-DOPA administration. Abnormal endogenous opioid signal transduction pathways in basal ganglia have been well documented in LID. Opioid receptors have been targeted to alleviate the dyskinesia. However, the exact role of this altered opioid activity is remains under active investigation. In the present review, we discuss the current understanding of opioid signal transduction in the basal ganglia and how the malfunction of opioid signaling contributes to the pathophysiology of LID. Further study of the opioid system in LID may lead to new therapeutic targets and improved treatment of PD patients.

    Original languageEnglish (US)
    Article number1
    JournalTranslational Neurodegeneration
    Volume6
    Issue number1
    DOIs
    StatePublished - Jan 17 2017

    ASJC Scopus subject areas

    • Clinical Neurology
    • Cognitive Neuroscience
    • Cellular and Molecular Neuroscience

    Fingerprint Dive into the research topics of 'Opioid system in L-DOPA-induced dyskinesia'. Together they form a unique fingerprint.

    Cite this